Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Hepatology

• Publication date

  2013-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jhep.2012.09.029PMID 23046671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HCV genotype-3a T cell immunity: specificity, function and impact of therapy

  2012cited by this paper
• Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.

  2012cited by this paper
• Natural killer cells and hepatitis C: Natural killer p46 expression linked to antiviral and antifibrotic activity

  2012cited by this paper
• NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner

  2012cited by this paper
• Virus-Induced Transient Immune Suppression and the Inhibition of T Cell Proliferation by Type I Interferon

  2011cited by this paper
• Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

  2011cited by this paper
• Role of the coinhibitory receptor cytotoxic T lymphocyte antigen‐4 on apoptosis‐Prone CD8 T cells in persistent hepatitis B virus infection

  2011cited by this paper
• Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.

  2011cited by this paper
• Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.

  2010cited by this paper
• Analysis of Apoptosis of Memory T Cells and Dendritic Cells during the Early Stages of Viral Infection or Exposure to Toll-Like Receptor Agonists

  2010cited by this paper
• Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection

  2010influential reference
• Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.

  2010cited by this paper
• Apoptosis of Hepatitis B Virus-Infected Hepatocytes Prevents Release of Infectious Virus

  2010cited by this paper
• Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.

  2010cited by this paper
• EASL Clinical Practice Guidelines: management of chronic hepatitis B.

  2009cited by this paper
• Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.

  2009cited by this paper
• Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection.

  2009cited by this paper
• Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates.

  2009cited by this paper
• Functions of natural killer cells

  2008cited by this paper
• Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection.

  2008cited by this paper
• Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage

  2007cited by this paper
• Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

  2003cited by this paper
• Coordinated and Distinct Roles for IFN-αβ, IL-12, and IL-15 Regulation of NK Cell Responses to Viral Infection1

  2002cited by this paper
• Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β 

  2001cited by this paper
• Virus-induced Transient Bone Marrow Aplasia: Major Role of Interferon-α/β during Acute Infection with the Noncytopathic Lymphocytic Choriomeningitis Virus

  1997cited by this paper
• Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B.

  1997cited by this paper
• Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e–minus hepatitis B virus mutants

  1995cited by this paper

• GLS4 Induces the Interferon Signaling Pathway During Hepatitis B Virus (HBV) Infection

  2026cites this paper
• Modeling Sound Speed of Aqueous Polyethylene Glycol Solutions

  2026cites this paper
• Comparative single-cell landscape of immune cells in human livers affected HBV and non-viral cirrhosis

  2026cites this paper
• Interferon-α enhances NK cell function to counteract autologous platelet-mediated tumor immune evasion

  2026cites this paper
• Interferon-α for Immune Modulation in Chronic Hepatitis B Toward Functional Cure

  2025cites this paper
• Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients.

  2025cites this paper
• In Vitro Transcribed Artificial Primary MicroRNA for the Inhibition of Hepatitis B Virus Gene Expression in Cultured Cells

  2025cites this paper
• Role of Immune Cells in Hepatitis B Virus and Associated Sequelae.

  2025cites this paper
• Predicting relapse after achieving a functional cure for chronic hepatitis B (CHB) using baseline HBsAg and end-of-treatment HBsAb levels

  2025cites this paper
• HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B

  2025cites this paper
• Targeting the innate immune system in treating hepatitis B: prospects for functional cure

  2025cites this paper
• Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection

  2025cites this paper
• Current status of drug therapy for chronic hepatitis B

  2025cites this paper
• Functional cure for chronic hepatitis B: A state of immune control over cccDNA persistence

  2025cites this paper
• Evolution of qHBsAg levels in HBV/HCV co-infected patients with low serum HBV DNA: Comparison between treated versus untreated.

  2025cites this paper
• Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T‐Cells Combined Antiviral Drugs in Treatment Naive CHB Patients‐A Multi‐Centre Phase II Study

  2025cites this paper
• Safety and efficacy of PD-1 antibody combined with pegylated interferon α for functional cure in nucleos(t)ide analogues-suppressed chronic hepatitis B patients: protocol for a multicentre randomised controlled trial

  2025cites this paper
• CD300A+ CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy

  2025cites this paper
• Antiviral therapy for hepatitis B virus infection is beneficial for the prognosis hepatocellular carcinoma

  2025cites this paper
• Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence‐Based Review on Emerging Clinical Data

  2024cites this paper
• Cytokine and chemokine profiling in chronic hepatitis C and B virus infections with high viral load.

  2024cites this paper
• HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B

  2024influential citation
• The immune response in chronic HBV infection

  2024cites this paper
• Achieving chronic hepatitis B functional cure: Factors and potential mechanisms

  2024cites this paper
• Nanocarrier‐Mediated RNA Delivery Platform as a Frontier Strategy for Hepatic Disease Treatment: Challenges and Opportunities

  2024cites this paper
• HBV Biomarkers and Their Role in Guiding Treatment Decisions

  2024cites this paper
• Elimination of the hepatitis B virus: A goal, a challenge

  2024cites this paper
• Mechanistic modeling to understand variability in responses to chronic Hepatitis B treatment

  2024cites this paper
• RNA Sequencing Analysis of Patients with Chronic Hepatitis B Treated Using PEGylated Interferon

  2024cites this paper
• Liver-restricted Type I IFN Signature Precedes Liver Damage in Chronic Hepatitis B Patients Stopping Antiviral Therapy.

  2024cites this paper
• Routine evaluation of HBV-specific T cell reactivity in chronic hepatitis B using a broad-spectrum T-cell epitope peptide library and ELISpot assay

  2024cites this paper
• Peripheral NK cell phenotypic alteration and dysfunctional state post hepatitis B subviral particles stimulation in CHB patients: evading immune surveillance

  2024cites this paper
• The scientific basis of combination therapy for chronic hepatitis B functional cure

  2023cites this paper
• Pegylated interferon-α for chronic hepatitis B…not ready to be shelved yet! new insights on its role using single-cell transcriptomics.

  2023cites this paper
• Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers

  2023cites this paper
• From hepatitis B virus infection to acute‐on‐chronic liver failure: The dynamic role of hepatic macrophages

  2023cites this paper
• Dynamic changes of the proportion of HLA-DR and CD38 coexpression subsets on T lymphocytes during IFN-based chronic hepatitis B treatment

  2023cites this paper
• Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B

  2023cites this paper
• Hepatitis B Virus Epsilon (ε) RNA Element: Dynamic Regulator of Viral Replication and Attractive Therapeutic Target

  2023cites this paper
• Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN

  2023cites this paper
• Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation

  2023cites this paper
• Predictive value of Th17 and Treg cells at baseline for HBsAg loss in chronic hepatitis B patients with low HBsAg quantification treated with pegylated interferon and nucleos(t)ide analogue

  2023cites this paper
• Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-α in patients with chronic hepatitis B

  2023cites this paper
• Liver-specific Inflammatory Signatures Predict Clinically Significant Liver Damage

  2023cites this paper
• Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.

  2023cites this paper
• Novel therapeutic strategies for chronic hepatitis B

  2022cites this paper
• Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy

  2022cites this paper
• CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients

  2022cites this paper
• Interferon‐based treatment of chronic hepatitis D

  2022cites this paper
• Enhanced host immune responses in presence of HCV facilitate HBV clearance in coinfection

  2022cites this paper
• Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection

  2022cites this paper
• An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis B patients

  2022cites this paper
• Engineered IFN-α and anti-PDL1 containing compounds to target the liver and restore antiviral protection for HBV cure

  2022cites this paper
• The immune landscape in hepatitis delta virus infection—Still an open field

  2022cites this paper
• Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse

  2022cites this paper
• The efficacy and safety of adding on or switching to peginterferon α‐2b in HBeAg‐positive chronic hepatitis B patients with long‐term entecavir treatment: a multicentre randomised controlled trial

  2022cites this paper
• IFNα subtype-specific susceptibility of HBV in the course of chronic infection

  2022cites this paper
• Cytokine profiles and CD8+ T cells in the occurrence of acute and chronic hepatitis B

  2022cites this paper
• Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg

  2022cites this paper
• Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure

  2022cites this paper
• Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine

  2022cites this paper
• Hepatitis B functional cure and immune response

  2022cites this paper
• Interleukin‐2 promotes pegylated interferon alpha for hepatitis B surface antigen loss: A retrospective pragmatic clinical study at the Fourth Affiliated Hospital of Zhejiang University Medical College

  2022cites this paper
• Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways.

  2022cites this paper
• Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure

  2021cites this paper
• Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection

  2021cites this paper
• Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition

  2021cites this paper
• Interferon α2–Thymosin α1 Fusion Protein (IFNα2–Tα1): A Genetically Engineered Fusion Protein with Enhanced Anticancer and Antiviral Effect

  2021cites this paper
• Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy

  2021cites this paper
• The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy

  2021cites this paper
• Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B

  2021cites this paper
• Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals

  2021cites this paper
• Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical

  2021cites this paper
• Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg-IFN-ɑ.

  2021cites this paper
• Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

  2021cites this paper
• Combination Therapy

  2021cites this paper
• Peg IFN-ɑ Treatment Enhanced the Inhibitory Effect of NK Cells on the Differentiation and Proliferation of CD4 +CD25 + Tregs via IFN-γ in Chronic Hepatitis B.

  2021cites this paper
• Interferon and Hepatitis B: Current and Future Perspectives

  2021cites this paper
• Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models.

  2021cites this paper
• Peg‐interferon alpha add‐on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg‐positive chronic hepatitis B naïve patients

  2021cites this paper
• Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss

  2021cites this paper
• Chronic Hepatitis B

  2021cites this paper
• Induction of T Cell Senescence by Cytokine Induced Bystander Activation

  2021influential citation
• Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary?

  2021cites this paper
• Case Report: Both Mother and Child With Chronic HBV Infection Were Clinically Cured After PEG-IFN Treatment

  2021cites this paper
• Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report

  2021cites this paper
• B Cell-mediated Humoral Immunity in Chronic Hepatitis B Infection

  2021cites this paper
• Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection

  2020cites this paper
• Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection

  2020cites this paper
• IFN-α Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation.

  2020cites this paper
• An Intracellular Model of Hepatitis B Viral Infection: An In Silico Platform for Comparing Therapeutic Strategies

  2020cites this paper
• Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

  2020cites this paper
• Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24+CD38hi B Cells

  2020cites this paper
• A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction

  2020cites this paper
• Clarifying the chemistry, activity, and safety of nucleic acid polymers.

  2020cites this paper
• In vitro inhibition effects of hepatitis B virus by dandelion and taraxasterol

  2020cites this paper
• Hepatitis B Core-Related Antigen Levels Predict Pegylated Interferon-α Therapy Response in HBeAg-Positive Chronic Hepatitis B

  2020cites this paper
• Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers predicting HBsAg loss

  2020cites this paper
• Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development.

  2020cites this paper
• Current knowledge on Hepatitis Delta Virus replication.

  2020cites this paper